Global Ingredient Risk Index Mineral

Potassium Iodide

Potassium iodide (KI)

Also known as: KI, potassium iodide, iodide supplement

27 მარ 2026

MODERATE RISK 4.5/10 How?

This ingredient is classified as unclassified risk (GIRI score: 4.5/10).

Known Safety Concerns

Triggers hypothyroidism and hyperthyroidism depending on thyroid status
Particularly dangerous in Hashimoto thyroiditis and nodular goitre
UL: 1,100 mcg/day -- exceeded by some iodine supplements
Interacts with thyroid medications and antithyroid drugs

Contraindications

Triggers hypothyroidism and hyperthyroidism depending on thyroid status
Particularly dangerous in Hashimoto thyroiditis and nodular goitre

═══════════════════════════════════════════════════════════════════════ -->

Information not yet available for this ingredient profile.

Potassium iodide is the pharmaceutical form of iodine used to supplement thyroid function. At the doses used in supplements it supports thyroid hormone synthesis. However chronic excess triggers both hypothyroidism (Wolff-Chaikoff effect) and hyperthyroidism (Jod-Basedow), particularly dangerous in individuals with nodular thyroid disease or autoimmune thyroid conditions. The UL is 1,100 mcg per day.

Scientific Name: Potassium iodide (KI)

Information not yet available for this ingredient profile.

SETI Score 50/100

Risk Level High risk

Scientific Confidence Low

Evidence Strength Limited

Key Benefit Mineral

Key Safety Concern Triggers hypothyroidism and hyperthyroidism depending on thyroid status

Evidence Reviewed 10 PubMed studies

Scientific Confidence Low

Based on study quality, consistency, and recency

Executive Summary — Ingredient Assessment

SETI Score 50/100

Risk Level High risk

Evidence Strength Limited

Main Benefit Mineral

Main Safety Concern Triggers hypothyroidism and hyperthyroidism depending on thyroid status

Ingredient Potassium Iodide

Scientific name Potassium iodide (KI)

Scientific Evidence Overview

10 studies reviewed
0 high-quality studies (meta-analysis or RCT)
Main clinical benefit observed: Mineral
Evidence consistency: High consistency across studies (100%)

Safety Signals

Triggers hypothyroidism and hyperthyroidism depending on thyroid status
Particularly dangerous in Hashimoto thyroiditis and nodular goitre
UL: 1,100 mcg/day -- exceeded by some iodine supplements
Interacts with thyroid medications and antithyroid drugs

Evidence Strength Limited

Final Scientific Assessment

The available scientific evidence for Potassium Iodide indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.

Ingredient Potassium Iodide

Evidence reviewed 10 peer-reviewed studies (last 10 years)

Scientific name Potassium iodide (KI)

50 /100

Total SETI Score

High risk

Evidence quality	10/40
Evidence consistency	20/20
Safety signals	0/20
Study recency	10/10
Evidence transparency	10/10

Evidence Summary

10 studies reviewed
0 high-quality studies (meta-analysis or systematic review)
0 studies identified benefits or no safety concern (GREEN)
10 studies reported limited or advisory safety evidence (YELLOW)

Evidence Policy

Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.

Last updated: 30 მარ 2026, 23:32

Evidence Distribution

10 Other / unclassified

Observational / other LOW evidence YELLOW
Efficacy of Conservative Approaches on the Physio-Mechanical Properties of Caries Lesions Remineralized with Silver Diamine Fluoride. ↗

PMID 41910230 ↗

Journal Oral Health Prev Dent

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41910230/

Al-Angari SS et al.. Efficacy of Conservative Approaches on the Physio-Mechanical Properties of Caries Lesions Remineralized with Silver Diamine Fluoride.. Oral Health Prev Dent. 2026. PMID:41910230.
Observational / other LOW evidence YELLOW
Repeated Sublethal Photodynamic Inactivation Does Not Increase Biofilm Formation or Induce Resistance in Acinetobacter baumannii. ↗

PMID 41864396 ↗

Journal Photodiagnosis Photodyn Ther

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41864396/

Qi Q et al.. Repeated Sublethal Photodynamic Inactivation Does Not Increase Biofilm Formation or Induce Resistance in Acinetobacter baumannii.. Photodiagnosis Photodyn Ther. 2026. PMID:41864396.
Observational / other LOW evidence YELLOW
Effectiveness of Tooth-colored Restorative Materials in Masking Discoloration Caused by Silver Diamine Fluoride: A Systematic Review of In Vitro Studies. ↗

PMID 41800005 ↗

Journal Int J Clin Pediatr Dent

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41800005/

Mathur A et al.. Effectiveness of Tooth-colored Restorative Materials in Masking Discoloration Caused by Silver Diamine Fluoride: A Systematic Review of In Vitro Studies.. Int J Clin Pediatr Dent. 2026. PMID:41800005.
Observational / other LOW evidence YELLOW
Comparative Evaluation of the Shear Bond Strength of Glass Ionomer Cement to Two Commercially Available Silver Diamine Fluoride Solutions in Primary Molars:… ↗

PMID 41799999 ↗

Journal Int J Clin Pediatr Dent

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41799999/

Baldawa H et al.. Comparative Evaluation of the Shear Bond Strength of Glass Ionomer Cement to Two Commercially Available Silver Diamine Fluoride Solutions in Primary Molars: An In Vitro Study.. Int J Clin Pediatr Dent. 2026. PMID:41799999.
Observational / other LOW evidence YELLOW
Iodide for the management of Graves' disease in pregnancy. ↗

PMID 41742197 ↗

Journal Thyroid Res

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41742197/

Yoshihara A et al.. Iodide for the management of Graves' disease in pregnancy.. Thyroid Res. 2026. PMID:41742197.
Observational / other LOW evidence YELLOW
Extracellular matrix-mimetic ink for 3D printing and minimally invasive delivery of shape-memory constructs. ↗

PMID 41624524 ↗

Journal Mater Today Bio

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41624524/

Tavakoli S et al.. Extracellular matrix-mimetic ink for 3D printing and minimally invasive delivery of shape-memory constructs.. Mater Today Bio. 2026. PMID:41624524.
Observational / other LOW evidence YELLOW
Clinical features of neonatal Graves' disease revealed by twelve cases that require- antithyroid therapy. ↗

PMID 41522420 ↗

Journal Clin Pediatr Endocrinol

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41522420/

Adachi E et al.. Clinical features of neonatal Graves' disease revealed by twelve cases that require- antithyroid therapy.. Clin Pediatr Endocrinol. 2026. PMID:41522420.
Observational / other LOW evidence YELLOW
Pre-Treatment With Potassium Iodide and Higher Radioiodine Dose Are the Risk Factors of Mid-to-Late-Phase Transient Thyrotoxicosis Following Radioiodine Therapy for Graves' Disease… ↗

PMID 41491627 ↗

Journal Clin Endocrinol (Oxf)

Year 2026

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41491627/

Matsuda E et al.. Pre-Treatment With Potassium Iodide and Higher Radioiodine Dose Are the Risk Factors of Mid-to-Late-Phase Transient Thyrotoxicosis Following Radioiodine Therapy for Graves' Disease in Japanese Patients: A Retrospective Cohort Study.. Clin Endocrinol (Oxf). 2026. PMID:41491627.
Observational / other LOW evidence YELLOW
Biocompatibility and antimicrobial efficacy of iodine-supported titania nanotubes on 3D-printed Ti-6Al-4V implants. ↗

PMID 41452929 ↗

Journal PLoS One

Year 2025

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41452929/

Taweekitikul P et al.. Biocompatibility and antimicrobial efficacy of iodine-supported titania nanotubes on 3D-printed Ti-6Al-4V implants.. PLoS One. 2025. PMID:41452929.
Observational / other LOW evidence YELLOW
How to discontinue potassium iodide in combined therapy with methimazole for initial treatment of Graves' disease. ↗

PMID 41443837 ↗

Journal Endocr J

Year 2025

Study type Observational / other

Evidence strength LOW evidence

PubMed link https://pubmed.ncbi.nlm.nih.gov/41443837/

Murakami T et al.. How to discontinue potassium iodide in combined therapy with methimazole for initial treatment of Graves' disease.. Endocr J. 2025. PMID:41443837.

Q × L × D × S × 10 = 4.5 / 10

The GIRI Score is the product of four independently computed evidence components, each normalised to 0–1, then scaled to 0–10. Every component is derived exclusively from peer-reviewed references and regulatory data — no editorial judgement is applied.

0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.

Method: Q = number of approved references ÷ 10 (capped at 1.0)

50%

Limited — mostly case reports or animal studies

Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.

Benefit

Risk

50%

Mixed or neutral — roughly equal benefit and risk signals

Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.

50%

One or more monitoring-level safety signals active

Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.

0Q × 5L × 5D × 5S = 4.5 / 10

Final GIRI Score for Potassium Iodide. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.

Full methodology & data sources

The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.

References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.

MODERATE RISK 4.5/10

Based on available regulatory signals and scientific evidence, this ingredient presents a moderate safety concern. Caution is advised, particularly at high doses or in sensitive populations.

LOW
0–3.0

MODERATE
3.0–5.5

HIGH
5.5–7.5

CRITICAL
7.5–10

4.5

The score pin shows exactly where this ingredient falls on the fixed risk scale.

What drove the Moderate classification for Potassium Iodide

A score of 4.5 places this ingredient in the Moderate band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.

0 approved references.

Limited — mostly case reports or animal studies (Level 4–5).

Neutral or mixed — benefit and risk signals roughly balanced.

No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.

No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).

How are the Low / Moderate / High / Critical thresholds defined?

The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:

Level	Score	Meaning
LOW	0.0 – 2.9	Sparse or predominantly beneficial evidence. No active safety alerts.
MODERATE	3.0 – 5.4	Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups.
HIGH	5.5 – 7.4	Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended.
CRITICAL	7.5 – 10	Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision.

Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.

← Back to Ingredient Database

Potassium Iodide

Safety Profile

Known Safety Concerns

Contraindications

Interactions

Evidence and Scientific Findings

Ingredient Overview

Biological and Chemical Classification

Mechanism of Action

Clinical Evidence of Effectiveness

Pharmacokinetics

Recommended Dosage

SETI — Scientific Evidence Transparency Index

Executive Summary — Ingredient Assessment

Evidence Summary

Evidence Policy

Evidence Distribution

Score Transparency

Risk Level Classification

What drove the Moderate classification for Potassium Iodide

ბოლო სიახლეები

500მლ პლასტმასის წყლის ბოთლები: ფარული საზოგადოებრივი ჯანმრთელობის რისკები

სკოლამდელი განათლება – მნიშვნელობა და გამოწვევები

ბავშვის უფლებები სკოლაში

პოპულარული ამბები

საუკეთესო ფილმები კულინარიის მოყვარულებისთვის

როგორ იყენებენ ახალგაზრდები ხელოვნურ ინტელექტს – სტუდენტების ხმა

კატეგორიები

ჩვენ შესახებ

გამოგვყევი სოციალურ ქსელებში